MSD’s Ontruzant Gets Australian Reimbursement
Follows PBS listings for Ogivri, Herzuma and Kanjinti
Merck Sharp & Dohme’s Ontruzant has become the fourth trastuzumab biosimilar to be reimbursed in Australia, while Pfizer’s Trazimera is in line to be the fifth.
